JP5746040B2 - 定常領域の中に改変を有する抗体変種 - Google Patents

定常領域の中に改変を有する抗体変種 Download PDF

Info

Publication number
JP5746040B2
JP5746040B2 JP2011539023A JP2011539023A JP5746040B2 JP 5746040 B2 JP5746040 B2 JP 5746040B2 JP 2011539023 A JP2011539023 A JP 2011539023A JP 2011539023 A JP2011539023 A JP 2011539023A JP 5746040 B2 JP5746040 B2 JP 5746040B2
Authority
JP
Japan
Prior art keywords
antibody
region
replaced
igg4
monovalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011539023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012510282A5 (enExample
JP2012510282A (ja
Inventor
アラン フランク ラブレイン
アラン フランク ラブレイン
ステファン ラブリクス
ステファン ラブリクス
ポール パーレン
ポール パーレン
デ ウィンケル ヤン ヴァン
デ ウィンケル ヤン ヴァン
ジャニーヌ スフールマン
ジャニーヌ スフールマン
イグナス ラスターズ
イグナス ラスターズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Publication of JP2012510282A publication Critical patent/JP2012510282A/ja
Publication of JP2012510282A5 publication Critical patent/JP2012510282A5/ja
Application granted granted Critical
Publication of JP5746040B2 publication Critical patent/JP5746040B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2011539023A 2008-12-03 2009-12-03 定常領域の中に改変を有する抗体変種 Active JP5746040B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200801709 2008-12-03
DKPA200801709 2008-12-03
PCT/EP2009/066290 WO2010063785A2 (en) 2008-12-03 2009-12-03 Antibody variants having modifications in the constant region

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015094864A Division JP6489924B2 (ja) 2008-12-03 2015-05-07 定常領域の中に改変を有する抗体変種

Publications (3)

Publication Number Publication Date
JP2012510282A JP2012510282A (ja) 2012-05-10
JP2012510282A5 JP2012510282A5 (enExample) 2013-01-24
JP5746040B2 true JP5746040B2 (ja) 2015-07-08

Family

ID=41692881

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011539023A Active JP5746040B2 (ja) 2008-12-03 2009-12-03 定常領域の中に改変を有する抗体変種
JP2015094864A Active JP6489924B2 (ja) 2008-12-03 2015-05-07 定常領域の中に改変を有する抗体変種

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015094864A Active JP6489924B2 (ja) 2008-12-03 2015-05-07 定常領域の中に改変を有する抗体変種

Country Status (7)

Country Link
US (5) US9085625B2 (enExample)
EP (2) EP3153524B1 (enExample)
JP (2) JP5746040B2 (enExample)
AU (3) AU2009324092A1 (enExample)
CA (2) CA2745439C (enExample)
SG (1) SG10201610247QA (enExample)
WO (1) WO2010063785A2 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
EP2615175B1 (en) 2007-05-31 2018-08-08 Genmab A/S Monovalent human antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CA2745439C (en) * 2008-12-03 2019-10-15 Genmab A/S Antibody variants having modifications in the constant region
CA2766166A1 (en) 2009-07-08 2011-01-13 Amgen Inc. Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
IN2014CN03887A (enExample) * 2011-10-27 2015-10-16 Genmab As
US20130273089A1 (en) 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
BR112014010532A2 (pt) 2011-11-03 2017-04-18 Tolera Therapeutics Inc anticorpo e métodos para inibição seletiva de respostas de célula-t
SG11201402485UA (en) 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
GB201203071D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
WO2013138643A1 (en) * 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Soluble engineered monomeric fc
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
ES2912396T3 (es) 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
CA3265373A1 (en) 2014-02-20 2025-10-30 H. Lundbeck A/S Anti-acth antibodies and use thereof
JP6825909B2 (ja) 2014-02-28 2021-02-03 アラコス インコーポレイテッド シグレック−８関連疾患を処置するための方法および組成物
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
KR20200029627A (ko) 2014-03-12 2020-03-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
EP3233907B1 (en) 2014-12-19 2021-03-03 Genmab A/S Rodent bispecific heterodimeric proteins
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
JP6786526B2 (ja) 2015-06-03 2020-11-18 ザ メディカル カレッジ オブ ウィスコンシン インクＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ Ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． 改変されたｃｃｌ２０ロックド二量体ポリペプチド
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
CA2992797A1 (en) 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
CA3025162A1 (en) 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
EP3515944A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHOD FOR TREATING IMMUNE DISEASES USING PD-1 BINDING PROTEINS
IL326479A (en) * 2016-10-12 2026-04-01 Bioverativ Usa Inc Anti-c1s antibodies and methods of use thereof
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
MX2019013136A (es) * 2017-05-05 2020-07-14 Allakos Inc Metodos y composiciones para tratar trastornos gastrointestinales inflamatorios.
BR112019022912A2 (pt) 2017-05-05 2020-05-26 Allakos Inc. Métodos e composições para tratar doenças oculares alérgicas
CN109034253B (zh) * 2018-08-01 2021-06-29 华中科技大学 一种基于多尺度语义特征的慢性静脉疾病图像分类方法
ES3009025T3 (en) 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
AU2020294879A1 (en) * 2019-06-19 2021-12-16 F. Hoffmann-La Roche Ag Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
CN112646041B (zh) * 2019-10-12 2023-11-10 上海睿智化学研究有限公司 包含抗体ch3域的异源二聚体及含其的抗体、融合蛋白
CA3169626A1 (en) 2020-03-19 2021-09-23 Genentech, Inc. Isoform-selective anti-tgf-beta antibodies and methods of use
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
MA71249A (fr) 2022-06-24 2025-04-30 Bioverativ Usa Inc. Méthodes de traitement de maladies médiées par complément
US12030945B2 (en) 2022-10-25 2024-07-09 Seismic Therapeutic, Inc. Variant IgG Fc polypeptides and uses thereof
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4593783B2 (ja) 1998-07-21 2010-12-08 ゲンマブ・アクティーゼルスカブ 抗ｃ型肝炎ウイルス抗体およびその使用
CN1399645A (zh) 1999-07-29 2003-02-26 米德列斯公司 Her2/neu的人单克隆抗体
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
JP4958555B2 (ja) * 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトＩｇＧ４抗体
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
EP1960431B1 (en) 2005-12-15 2014-10-01 Genmab A/S Use of effector-function-deficient antibodies for treatment of auto-immune diseases
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
EP2152751A1 (en) * 2007-05-31 2010-02-17 Genmab A/S Fusion or linked proteins with extended half life
US20100255012A1 (en) * 2007-05-31 2010-10-07 Genmab A/S Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering
CA2689895A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Non-glycosylated recombinant monovalent antibodies
EP2615175B1 (en) * 2007-05-31 2018-08-08 Genmab A/S Monovalent human antibodies
AU2008255352B2 (en) * 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
WO2008145141A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
CA2745439C (en) * 2008-12-03 2019-10-15 Genmab A/S Antibody variants having modifications in the constant region
UA109633C2 (uk) * 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
CN104262483A (zh) * 2009-01-26 2015-01-07 根马布股份公司 用于生成抗体混合物的方法

Also Published As

Publication number Publication date
US20110293607A1 (en) 2011-12-01
AU2016200663B2 (en) 2017-11-30
EP2373687B1 (en) 2016-10-26
CA2745439C (en) 2019-10-15
JP2015180648A (ja) 2015-10-15
US20210155699A1 (en) 2021-05-27
AU2016200663A1 (en) 2016-02-18
EP3153524A1 (en) 2017-04-12
AU2018201377A1 (en) 2018-03-15
WO2010063785A2 (en) 2010-06-10
JP6489924B2 (ja) 2019-03-27
US9085625B2 (en) 2015-07-21
US20150368345A1 (en) 2015-12-24
US20180319888A1 (en) 2018-11-08
US20150376282A1 (en) 2015-12-31
EP2373687A2 (en) 2011-10-12
SG10201610247QA (en) 2017-02-27
EP3153524B1 (en) 2025-04-23
WO2010063785A3 (en) 2010-07-29
CA2745439A1 (en) 2010-06-10
JP2012510282A (ja) 2012-05-10
AU2018201377B2 (en) 2020-05-21
AU2009324092A1 (en) 2011-06-23
CA3053156A1 (en) 2010-06-10
US10000570B2 (en) 2018-06-19

Similar Documents

Publication Publication Date Title
JP6489924B2 (ja) 定常領域の中に改変を有する抗体変種
JP6412083B2 (ja) 安定なＩｇＧ４抗体
EP3875485A1 (en) Bispecific antibody binding to cd20 and cd3 and uses thereof
JP5511654B2 (ja) 分子操作により得られた組換え非グリコシル化一価半抗体
JP7834654B2 (ja) Ｓｔ２抗原結合タンパク質
WO2023208016A1 (en) Single-chain fragment variable comprising mutant light chain framework region
JP7797622B2 (ja) ヒトインターロイキン－４受容体アルファ抗体
HK1163128B (en) Igg4 antibody variants having modifications in the constant region
HK1163128A (en) Igg4 antibody variants having modifications in the constant region
CN118055948A (zh) 人白细胞介素4受体α抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121130

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20131031

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20131031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140805

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150507

R150 Certificate of patent or registration of utility model

Ref document number: 5746040

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350